{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:29:35Z","timestamp":1785569375856,"version":"3.56.0"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with severe B\u2010cell depletion related to hematological malignancies or B\u2010cell targeted therapy suffer from impaired antibody responses to SARS\u2010CoV\u20102 and are at risk for prolonged COVID\u201019. In this population, COVID\u201019 convalescent plasma (CCP) may provide passive immunity, enhance immune response, and promote virus neutralization. This study evaluated outcomes of B\u2010cell depleted patients with persistent COVID\u201019 treated with CCP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design and Methods<\/jats:title><jats:p>This analysis included all consecutive severely B\u2010cell depleted patients with persistent COVID\u201019, receiving CCP at Rambam between 01.2022\u201302.2023. Persistent COVID\u201019 was defined as the presence of symptoms for \u226514\u2009days in patients with negative SARS\u2010CoV\u20102 nucleocapsid antibody test results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty patients met inclusion criteria, 17 of whom had hematological malignancies, two suffered from rheumatoid arthritis and one had both. Twelve patients received anti\u2010CD\u201020 treatment, one \u2010 CAR\u2010T cells and three underwent stem cell transplantation. The median duration of COVID\u201019 symptoms was 27.5\u2009days (range 14\u201397); 12 patients had mild\u2010to\u2010moderate COVID\u201019 and 8 had severe infection. Sixteen patients required hospitalization. The majority of patients received other COVID\u201019 therapies before CCP. Within a median of two days (range 1\u201316) post\u2010infusion, 19\/20 patients clinically improved. No CCP\u2010associated adverse events were documented. COVID\u201019 symptoms recurred in 3 of the improved patients. Two patients died from COVID\u201019 on days 1 and 90 following the first CCP infusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In severely B\u2010cell depleted patients with persistent COVID\u201019, CCP is safe and associated with rapid clinical improvement. This subset of immunocompromised patients could particularly benefit from CCP administration.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.17737","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T08:44:06Z","timestamp":1707381846000},"page":"443-448","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Charting a path forward: Promising outcomes of convalescent plasma therapy in the care of severely <scp>B\u2010cell<\/scp> depleted patients with persistent <scp>COVID<\/scp>\u201019"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9327-5999","authenticated-orcid":false,"given":"Tsofia","family":"Inbar","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Rambam Health Care Campus  Haifa Israel"},{"name":"Blood Bank and Apheresis Unit Rambam Health Care Campus  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldad J.","family":"Dann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation Rambam Health Care Campus  Haifa Israel"},{"name":"Blood Bank and Apheresis Unit Rambam Health Care Campus  Haifa Israel"},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kerner","sequence":"additional","affiliation":[{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Stern","sequence":"additional","affiliation":[{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology  Haifa Israel"},{"name":"Division of Infectious Diseases Rambam Health Care Campus  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1033"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.10.007"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2023.01.024"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01177-0"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3064"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100403"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194629"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817829"},{"key":"e_1_2_11_11_1","unstructured":"Coronavirus Disease 2019 (COVID\u201019) Treatment Guidelines.COVID\u201019 Convalescent Plasma: National Institutes of Health (US). Available from:https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antivirals-including-antibody-products\/covid-19-convalescent-plasma\/Accessed May 2023."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50647"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad066"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01920-1"},{"key":"e_1_2_11_15_1","unstructured":"COVID\u201019 Treatment Guidelines Panel.Coronavirus Disease 2019 (COVID\u201019) Treatment Guidelines. National Institutes of Health. Available from:https:\/\/files.covid19treatmentguidelines.nih.gov\/guidelines\/covid19treatmentguidelines.pdfAccessed July 2023."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01511-6"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1799"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2021.2013528"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3060"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008423"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17266"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007410"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001854"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008932"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.17737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T06:20:46Z","timestamp":1710570046000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.17737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1111\/trf.17737"],"URL":"https:\/\/doi.org\/10.1111\/trf.17737","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"assertion":[{"value":"2023-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}